A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported a larger-than-expected loss for Q1 FY2025, with earnings per share (EPS) at -$1.39, missing the forecast of -$0.39. Revenue also fell short ...

When shopping for resveratrol supplements, choose a reputable brand, and follow the recommended dosage guidelines. Koushki M, Amiri-Dashatan N, Ahmadi N, et al. Resveratrol: A miraculous natural ...

Charts and graphs provided within are for informational purposes ... change without notice and may differ or be contrary to opinions expressed by others. The Compound Media, Inc., an affiliate of ...

Change orientation to land scape to view the price table ...